KR102752259B1 - 인자 h 결합 단백질 변이체 및 이의 사용 방법 - Google Patents

인자 h 결합 단백질 변이체 및 이의 사용 방법 Download PDF

Info

Publication number
KR102752259B1
KR102752259B1 KR1020177004378A KR20177004378A KR102752259B1 KR 102752259 B1 KR102752259 B1 KR 102752259B1 KR 1020177004378 A KR1020177004378 A KR 1020177004378A KR 20177004378 A KR20177004378 A KR 20177004378A KR 102752259 B1 KR102752259 B1 KR 102752259B1
Authority
KR
South Korea
Prior art keywords
fhbp
gly
amino acid
variant
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177004378A
Other languages
English (en)
Korean (ko)
Other versions
KR20170028442A (ko
Inventor
피터 티. 비어닝크
Original Assignee
칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 filed Critical 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드
Priority to KR1020237036853A priority Critical patent/KR102761870B1/ko
Publication of KR20170028442A publication Critical patent/KR20170028442A/ko
Application granted granted Critical
Publication of KR102752259B1 publication Critical patent/KR102752259B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177004378A 2014-07-23 2015-07-22 인자 h 결합 단백질 변이체 및 이의 사용 방법 Active KR102752259B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237036853A KR102761870B1 (ko) 2014-07-23 2015-07-22 인자 h 결합 단백질 변이체 및 이의 사용 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462028123P 2014-07-23 2014-07-23
US62/028,123 2014-07-23
PCT/US2015/041616 WO2016014719A1 (en) 2014-07-23 2015-07-22 Factor h binding protein variants and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237036853A Division KR102761870B1 (ko) 2014-07-23 2015-07-22 인자 h 결합 단백질 변이체 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20170028442A KR20170028442A (ko) 2017-03-13
KR102752259B1 true KR102752259B1 (ko) 2025-01-13

Family

ID=55163727

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177004378A Active KR102752259B1 (ko) 2014-07-23 2015-07-22 인자 h 결합 단백질 변이체 및 이의 사용 방법
KR1020237036853A Active KR102761870B1 (ko) 2014-07-23 2015-07-22 인자 h 결합 단백질 변이체 및 이의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237036853A Active KR102761870B1 (ko) 2014-07-23 2015-07-22 인자 h 결합 단백질 변이체 및 이의 사용 방법

Country Status (15)

Country Link
US (10) US10266572B2 (cg-RX-API-DMAC10.html)
EP (2) EP4074726A3 (cg-RX-API-DMAC10.html)
JP (4) JP6796057B2 (cg-RX-API-DMAC10.html)
KR (2) KR102752259B1 (cg-RX-API-DMAC10.html)
CN (3) CN112851768A (cg-RX-API-DMAC10.html)
AU (5) AU2015292615B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017001417B1 (cg-RX-API-DMAC10.html)
CA (2) CA3212723A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017000558A2 (cg-RX-API-DMAC10.html)
CR (1) CR20170020A (cg-RX-API-DMAC10.html)
ES (1) ES2922554T3 (cg-RX-API-DMAC10.html)
MX (3) MX382409B (cg-RX-API-DMAC10.html)
NZ (2) NZ766005A (cg-RX-API-DMAC10.html)
RU (1) RU2714248C2 (cg-RX-API-DMAC10.html)
WO (1) WO2016014719A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201802933T4 (tr) 2010-03-30 2018-03-21 Childrens Hospital & Res Center At Oakland Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
BR112017001417B1 (pt) 2014-07-23 2023-11-07 Children's Hospital & Research Center At Oakland Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
KR101855133B1 (ko) 2016-11-16 2018-05-08 주식회사 케이엠더블유 적층구조의 mimo 안테나 어셈블리
WO2018093176A2 (ko) 2016-11-16 2018-05-24 주식회사 케이엠더블유 적층구조의 mimo 안테나 어셈블리
KR102822764B1 (ko) * 2017-12-04 2025-06-19 인트라백 비.브이. 외막 소포의 생성을 위한 개선된 방법
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
GB202016604D0 (en) 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組ｂ型腦膜炎球菌疫苗
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2026072910A1 (en) 2024-09-27 2026-04-02 Sanofi Pasteur Inc. Anti-meningococcal antibodies for in vitro immunoassay

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060251670A1 (en) 2002-11-22 2006-11-09 Maurizio Comanducci Multiple variants of meningococcal protein nmb1870
US20060257413A1 (en) 2001-10-11 2006-11-16 Zlotnick Gary W Novel immunogenic compositions for the prevention and treatment of meningococcal disease
US20070031449A1 (en) 2003-12-23 2007-02-08 Bos Martine P Vaccine
US20110256180A1 (en) * 2010-03-30 2011-10-20 Beernink Peter T Factor H Binding Proteins (FHBP) with Altered Properties and Methods of Use Thereof
US20110318378A1 (en) 2008-09-03 2011-12-29 Peter Beernink Peptides Presenting an Epitope of a Domain of Factor H Binding Protein and Methods of Use
US20120052092A1 (en) 2008-10-25 2012-03-01 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein
US20120093867A1 (en) 2005-01-27 2012-04-19 Granoff Dan M GNA1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis
WO2015017817A1 (en) 2013-08-02 2015-02-05 Children's Hospital & Research Center Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
IL148671A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
HK1049106A1 (zh) 1999-09-24 2003-05-02 Smithkline Beecham Biologicals S.A. 聚氧化乙烯山梨糖酯和octooxynol的聯用做為佐劑和其在疫苗中的用途
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
AU2013206190A1 (en) 1999-11-29 2013-06-27 Novartis Vaccines And Diagnostics S.R.L. Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
PT2270030E (pt) 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US6839862B2 (en) 2001-05-31 2005-01-04 Koninklijke Philips Electronics N.V. Parallel data communication having skew intolerant data groups
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
WO2004074433A2 (en) 2003-01-30 2004-09-02 Yale University Rag polypeptides, nucleic acids, and their use
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
ZA200707420B (en) 2005-02-14 2009-04-29 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2009038889A1 (en) 2007-08-02 2009-03-26 Children's Hospital And Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
AU2009215364B2 (en) * 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
AU2009223613B2 (en) * 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
US8476032B2 (en) 2008-08-27 2013-07-02 Children's Hospital & Research Center Oakland Complement factor H-based assays for serum bactericidal activity against Neisseria meningitidis
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
CN104548082A (zh) 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
US9266942B2 (en) 2009-04-30 2016-02-23 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHbp) and methods of use
CA2779816A1 (en) * 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
KR101584871B1 (ko) * 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CN102028941B (zh) 2011-02-11 2013-02-13 中国医学科学院医学生物学研究所 一种b群脑膜炎球菌重组蛋白嵌合疫苗及其制备方法
EP2729167B1 (en) 2011-07-07 2018-03-14 De Staat der Nederlanden, vert. door de Minister van VWS A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
WO2013078223A1 (en) 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
CA2865745C (en) * 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
CN106661092B (zh) 2014-02-28 2021-07-06 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
KR20150128099A (ko) 2014-05-08 2015-11-18 (주)엘지하우시스 Pla 및 pha 혼합수지를 이용한 벽지 및 그 제조 방법
CN107349423B (zh) * 2014-06-24 2021-03-19 上海生物制品研究所有限责任公司 一种脑膜炎球菌抗原组合及其应用
MX2017000776A (es) * 2014-07-17 2017-05-04 Glaxosmithkline Biologicals Sa Polipeptidos fhbp meningococicos modificados.
BR112017001417B1 (pt) 2014-07-23 2023-11-07 Children's Hospital & Research Center At Oakland Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257413A1 (en) 2001-10-11 2006-11-16 Zlotnick Gary W Novel immunogenic compositions for the prevention and treatment of meningococcal disease
US20060251670A1 (en) 2002-11-22 2006-11-09 Maurizio Comanducci Multiple variants of meningococcal protein nmb1870
US20070031449A1 (en) 2003-12-23 2007-02-08 Bos Martine P Vaccine
US20120093867A1 (en) 2005-01-27 2012-04-19 Granoff Dan M GNA1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis
US20110318378A1 (en) 2008-09-03 2011-12-29 Peter Beernink Peptides Presenting an Epitope of a Domain of Factor H Binding Protein and Methods of Use
US20120052092A1 (en) 2008-10-25 2012-03-01 Imperial Innovations Limited Vaccine compositions comprising a mutated factor h binding protein
US20110256180A1 (en) * 2010-03-30 2011-10-20 Beernink Peter T Factor H Binding Proteins (FHBP) with Altered Properties and Methods of Use Thereof
AU2011238670A1 (en) 2010-03-30 2012-09-13 Children's Hospital & Research Center Oakland Factor H binding proteins (FHBP) with altered properties and methods of use thereof
WO2015017817A1 (en) 2013-08-02 2015-02-05 Children's Hospital & Research Center Oakland Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof

Also Published As

Publication number Publication date
AU2025202774A1 (en) 2025-05-08
US20170183384A1 (en) 2017-06-29
US10836799B2 (en) 2020-11-17
US10995122B2 (en) 2021-05-04
MX2023000204A (es) 2023-02-09
CA2955802A1 (en) 2016-01-28
JP2021000121A (ja) 2021-01-07
MX2021005373A (es) 2021-07-06
US20240025951A1 (en) 2024-01-25
US10266572B2 (en) 2019-04-23
EP4074726A3 (en) 2022-11-23
US11673920B2 (en) 2023-06-13
CN106715464B (zh) 2021-03-16
US12129282B2 (en) 2024-10-29
US20210101942A1 (en) 2021-04-08
JP2023011916A (ja) 2023-01-24
RU2017104742A3 (cg-RX-API-DMAC10.html) 2019-02-27
JP2025108722A (ja) 2025-07-23
AU2021203828B2 (en) 2023-04-13
US20190225655A1 (en) 2019-07-25
US20250136648A1 (en) 2025-05-01
KR102761870B1 (ko) 2025-02-05
CR20170020A (es) 2017-08-10
US10487122B2 (en) 2019-11-26
AU2019264600A1 (en) 2019-12-05
NZ766003A (en) 2024-01-26
EP4074726A2 (en) 2022-10-19
RU2017104742A (ru) 2018-08-29
EP3172224A4 (en) 2018-04-18
AU2019264600B2 (en) 2021-04-01
NZ766005A (en) 2024-03-22
KR20170028442A (ko) 2017-03-13
EP3172224B1 (en) 2022-06-29
AU2021203828A1 (en) 2021-07-08
CO2017000558A2 (es) 2017-06-20
US20200095288A1 (en) 2020-03-26
AU2023204391B2 (en) 2025-01-23
CN112851768A (zh) 2021-05-28
AU2023204391A1 (en) 2023-08-03
US12269849B2 (en) 2025-04-08
AU2025202774A9 (en) 2026-03-05
CA3212723A1 (en) 2016-01-28
US20250154206A1 (en) 2025-05-15
ES2922554T3 (es) 2022-09-16
AU2015292615A1 (en) 2017-03-16
RU2714248C2 (ru) 2020-02-13
NZ729206A (en) 2022-07-01
AU2015292615B2 (en) 2019-10-24
EP3172224A1 (en) 2017-05-31
JP7719046B2 (ja) 2025-08-05
US11834476B2 (en) 2023-12-05
JP2017522877A (ja) 2017-08-17
KR20230155595A (ko) 2023-11-10
CA2955802C (en) 2023-10-31
BR112017001417A2 (pt) 2017-11-21
JP6796057B2 (ja) 2020-12-02
MX382409B (es) 2025-03-13
US20200109179A1 (en) 2020-04-09
CN106715464A (zh) 2017-05-24
JP7221917B2 (ja) 2023-02-14
MX2017001038A (es) 2018-02-09
RU2020105192A (ru) 2020-02-12
CN119613509A (zh) 2025-03-14
BR112017001417B1 (pt) 2023-11-07
WO2016014719A1 (en) 2016-01-28
NZ766444A (en) 2024-01-26
US20210340191A1 (en) 2021-11-04
US20240101610A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
US12269849B2 (en) Factor H binding protein variants and methods of use thereof
HK40076049A (en) Factor h binding protein variants and methods of use thereof
RU2811942C2 (ru) Варианты фактор h-связывающего белка и способы их применения
HK1238266A1 (en) Factor h binding protein variants and methods of use thereof
HK1238266B (en) Factor h binding protein variants and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101002291; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20231026

Effective date: 20241014

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20241014

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2017 7004378

Appeal request date: 20231026

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2023101002291

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PA0102 Application to register extension of term of patent right following delayed registration

St.27 status event code: A-4-4-G10-G15-tad-PA0102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 147

G17 Pta granted

Free format text: ST27 STATUS EVENT CODE: A-4-4-G10-G17-TAD-PR1102 (AS PROVIDED BY THE NATIONAL OFFICE)

PR1102 Extension of patent period due to registration delay

St.27 status event code: A-4-4-G10-G17-tad-PR1102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 210